RecruitingNCT06604039

A Clinical Registry to Demonstrate the Safety and Performance of Teleflex Vascular Access Devices

A Prospective Clinical Registry Evaluating Safety and Performance of Teleflex Vascular Access Devices


Sponsor

Teleflex

Enrollment

2,500 participants

Start Date

Dec 8, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The general objective of Teleflex's Vascular Access Device Registry (VADER) is to provide high-quality Level 3 (or better) data on the performance, safety and clinical benefits of Teleflex's vascular access devices when used in a real-world setting


Eligibility

Inclusion Criteria3

  • Subjects will undergo a procedure that will include use of a Teleflex device covered by this Research.
  • Subject is willing and capable of providing informed consent and/or give approval to collect, store and process limited health information by the Sponsor; or such consent is provided by a legally designated representative if required by local law or regulation.
  • Subjects is able to read and understand English or Spanish languages

Exclusion Criteria4

  • Subject is currently participating in another clinical Registry or investigation that may confound the results of this Registry.
  • Subject was previously failed screening or was enrolled in this clinical Registry.
  • Subject is imprisoned
  • Subject is cognitively impaired and unable to provide informed consent

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICECentral venous catheter

Placement of a medical device to gain entry into the bloodstream, typically through a vein or artery, for the purpose of administering fluids, medications, blood products, or for hemodialysis


Locations(3)

Huntsville Hospital

Huntsville, Alabama, United States

Loma Linda University Health

Loma Linda, California, United States

Tufts Medical Center

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06604039


Related Trials